218 related articles for article (PubMed ID: 15608425)
41. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
[TBL] [Abstract][Full Text] [Related]
42. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
[TBL] [Abstract][Full Text] [Related]
43. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
44. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
45. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
46. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
47. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
Hung CF; Calizo R; Tsai YC; He L; Wu TC
Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
[TBL] [Abstract][Full Text] [Related]
48. IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.
Martorelli D; Guidoboni M; De Re V; Muraro E; Turrini R; Merlo A; Pasini E; Caggiari L; Romagnoli L; Spina M; Mortarini R; Gasparotto D; Mazzucato M; Carbone A; Rosato A; Anichini A; Dolcetti R
Clin Cancer Res; 2012 Aug; 18(15):4080-91. PubMed ID: 22705988
[TBL] [Abstract][Full Text] [Related]
49. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Yamamoto T; Furuya N; Whiteside TL; Masuyama K
Oral Oncol; 2008 Sep; 44(9):870-7. PubMed ID: 18221909
[TBL] [Abstract][Full Text] [Related]
50. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
[TBL] [Abstract][Full Text] [Related]
51. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx.
Hoffmann TK; Arsov C; Schirlau K; Bas M; Friebe-Hoffmann U; Klussmann JP; Scheckenbach K; Balz V; Bier H; Whiteside TL
Int J Cancer; 2006 Apr; 118(8):1984-91. PubMed ID: 16284959
[TBL] [Abstract][Full Text] [Related]
52. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.
Chikamatsu K; Sakakura K; Takahashi G; Okamoto A; Furuya N; Whiteside TL; DeLeo AB; Masuyama K
Cancer Immunol Immunother; 2009 Sep; 58(9):1441-8. PubMed ID: 19184003
[TBL] [Abstract][Full Text] [Related]
53. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.
Röpke M; Hald J; Guldberg P; Zeuthen J; Nørgaard L; Fugger L; Svejgaard A; Van der Burg S; Nijman HW; Melief CJ; Claesson MH
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14704-7. PubMed ID: 8962118
[TBL] [Abstract][Full Text] [Related]
54. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
Andrade Filho PA; Ito D; Deleo AB; Ferris RL
Cancer Immunol Immunother; 2010 Oct; 59(10):1561-8. PubMed ID: 20577877
[TBL] [Abstract][Full Text] [Related]
55. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
Albers AE; Ferris RL; Kim GG; Chikamatsu K; DeLeo AB; Whiteside TL
Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774
[TBL] [Abstract][Full Text] [Related]
56. [Detection of specific T cells for 264-272 and 149-157 peptides of p53 protein in peripheral blood of patients with breast cancer].
Alvarez-Busto I; Albers A; Visus MC; Mayordomo JI; Sanz J; Burillo MA; Güemes A; García-Prats MD; Moros M; De Leo A; Tres A
Med Clin (Barc); 2008 Nov; 131(18):685-8. PubMed ID: 19087825
[TBL] [Abstract][Full Text] [Related]
57. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
Herold-Mende C; Karcher J; Dyckhoff G; Schirrmacher V
Adv Otorhinolaryngol; 2005; 62():173-83. PubMed ID: 15608427
[TBL] [Abstract][Full Text] [Related]
58. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
59. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P
Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101
[TBL] [Abstract][Full Text] [Related]
60. EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma.
Schuler PJ; Boeckers P; Engers R; Boelke E; Bas M; Greve J; Dumitru CA; Lehnerdt GF; Ferris RL; Andrade Filho PA; Brandau S; Lang S; Whiteside TL; Hoffmann TK
J Transl Med; 2011 Oct; 9():168. PubMed ID: 21970318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
